 ROCHESTER, N.Y., Sept. 17, 2021 GLOBE NEWSWIRE -- Vaccinex, Inc. Nasdaq: VCNX, a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer Co. Inc. Fall Healthcare Life Sciences and MedTech Summit. 